4.10.25.3Vertical

Pediatric Rheumatology Programs

Specialists treating juvenile arthritis and pediatric autoimmune conditions.

Market snapshot

These figures describe Rheumatology (4.10.25), the segment that Pediatric Rheumatology Programs sits within. They are not figures for Pediatric Rheumatology Programs on its own.

FragmentationConsolidatingEstimate

Within Offices of Physicians (NAICS 621111); the Census Bureau does not split physician offices by specialty, so rheumatology is not separately sized.

Business model & economics

Revenue model

Office reimbursement plus in-office biologic infusion margin

Key economics

Recurring revenue
High

chronic autoimmune care and infusion

EBITDA margin
18–28% with infusion ancillaries
Capex intensity
Low

Characteristics

  • In-office biologic infusion drives ancillary economics.
  • Autoimmune prevalence and biologics growth.
  • Rheumatologist shortage and emerging MSO interest.

M&A deal context

Deal activityModerate

Who’s acquiring

  • Infusion-focused MSO platforms
  • PE-backed rheumatology consolidators
  • Multispecialty acquirers

What’s driving deals

  • Roll-up for infusion ancillary economics.
  • Autoimmune and biologics demand.
  • Rheumatologist shortage.

Find Pediatric Rheumatology Programs acquisition targets

Search Acquisera’s index for companies classified under Pediatric Rheumatology Programs (4.10.25.3) and build a targeted deal pipeline.

Search companies